I perform in-laboratory testing of new drugs that have been developed for acute myeloid leukemia (AML). These drugs are being tested in clinical trials in adults, and may be useful for children with AML as well. I'm also trying to develop more sensitive methods to detect molecular disease when it is not otherwise detectable after therapy, so we can more accurately know how much therapy is needed for individual patients.
For Referring Providers:
I am investigating targeted therapies for pediatric AML in the pre-clinical setting, including immunotherapies. In addition, I am developing droplet digital PCR assays as an alternative means to measure minimal residual disease in patients with AML.